eptacog alfa (activated) + placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Bleeding Disorder
Conditions
Acquired Bleeding Disorder, Trauma
Trial Timeline
Oct 1, 2005 → Sep 1, 2008
NCT ID
NCT00184548About eptacog alfa (activated) + placebo
eptacog alfa (activated) + placebo is a phase 3 stage product being developed by Novo Nordisk for Acquired Bleeding Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00184548. Target conditions include Acquired Bleeding Disorder, Trauma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00184548 | Phase 3 | Terminated |
Competing Products
20 competing products in Acquired Bleeding Disorder